In vitro and in vivo activities of DW-3-15, a commercial praziquantel derivative, against Schistosoma japonicum
Open Access
- 3 May 2019
- journal article
- research article
- Published by Springer Nature in Parasites & Vectors
- Vol. 12 (1) , 199
Abstract
Schistosomiasis is a debilitating neglected tropical disease that affects approximately 190 million people around the world. Praziquantel (PZQ) is the only drug available for use against all Schistosoma species. Although PZQ has a high efficacy, recognized concerns have prompted the development of new, alternative drugs for repeated use in endemic areas where PZQ efficacy against strains of Schistosoma is reduced. A hybrid drug containing different pharmacophores within a single molecule is a promising strategy. Our earlier in vivo studies showed the significant antiparasitic activity of a praziquantel derivative, DW-3-15, against Schistosoma japonicum. In the present study, DW-3-15 was synthesized in large amounts by a pharmaceutical company and its schistosomicidal efficacy and stability were further confirmed. Parameters such as parasite viability, pairing and oviposition were evaluated in vitro. An in vivo study was conducted to assess the effect of commercial DW-3-15 on worm burden, egg production and diameter of granulomas. Additionally, to gain insight into the mechanism of action for DW-3-15, morphological changes in the tegument of S. japonicum were also examined. The in vitro study showed the antiparasitic activity of DW-3-15 against S. japonicum, with significant reductions in viability of adult and juvenile worms, worm pairings and egg output. Compared to PZQ, DW-3-15 induced similar ultrastructural changes and evident destruction of the tegument surface in male worms. In vivo, the oral administration of DW-3-15 at a dose of 400 mg/kg per day for five consecutive days in mice significantly reduced the total worm burden and number of eggs in the liver. Histological analysis of the livers showed a marked reduction in the average diameter of the egg granuloma. Our findings suggest that DW-3-15, a PZQ derivative with the prospect of commercial production, can be developed as a potential promising schistosomicide.Keywords
Funding Information
- Natural Science Foundation of China (81772216)
- Key Projects of Science Research in Education Institutes of Anhui Colleges and Universities (KJ2016A708)
- Priority Academic Program Development of Jiangsu Higher Education Institutions
This publication has 47 references indexed in Scilit:
- Susceptibility or resistance of praziquantel in human schistosomiasis: a reviewParasitology Research, 2012
- Antischistosomal Activity of Trioxaquines: In Vivo Efficacy and Mechanism of Action on Schistosoma mansoniPLOS Neglected Tropical Diseases, 2012
- Ultrastructural alterations of juvenile Schistosoma japonicum harbored in mice following mefloquine administrationParasitology Research, 2011
- Trioxaquine PA1259 Alkylates Heme in the Blood-Feeding Parasite Schistosoma mansoniAntimicrobial Agents and Chemotherapy, 2011
- Efficacy and Safety of Mefloquine, Artesunate, Mefloquine‐Artesunate, and Praziquantel againstSchistosoma haematobium: Randomized, Exploratory Open‐Label TrialClinical Infectious Diseases, 2010
- Praziquantel analogs with activity against juvenile Schistosoma mansoniBioorganic & Medicinal Chemistry Letters, 2010
- Mefloquine—An Aminoalcohol with Promising Antischistosomal Properties in MicePLOS Neglected Tropical Diseases, 2009
- Qinghaosu (Artemisinin): The Price of SuccessScience, 2008
- Identification of oxadiazoles as new drug leads for the control of schistosomiasisNature Medicine, 2008
- Molecular Characterization of aCryptosporidiumIsolate From a Black BearJournal of Parasitology, 2000